Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast
The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore, a series of approvals expected in the next decade will likely present a challenge to the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies and drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the positions of current market leaders. The impending entry of the first TYK2 inhibitor (BMS’s deucravacitinib), an additional IL-17 inhibitor (UCB’s bimekizumab), and an IL-23 inhibitor (Sun Pharma’s tildrakizumab) will also create interesting market dynamics.
Questions answered
- What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in different markets react to these less-expensive therapies?
- How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What is the physician perception of these therapies?
- Which emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? What novel mechanisms of action are considered good clinical targets for this disease?
- Which unmet needs remain in the treatment of PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?
Content highlights:
Geographies: United States, EU5, Japan.
Primary research: Approximately 20 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2031, segmented by brands / generics.
Emerging therapies: Phase III/PR: 3 drugs; Phase II: 5 drugs.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- August 2023
- May 2023
- March 2023
- Q4 2022
- December 2022
- October 2022
- Q3 2022
- September 2022
- August 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Market outlook
- Key findings
- Market share of drug classes for PsA: 2021
- Market share of drug classes for PsA: 2031
- PsA SWOT analysis
- Market drivers and constraints
- What factors are driving the market for PsA?
- What factors are constraining the market for PsA?
- Annual sales of TNF inhibitors in PsA: 2021-2031
- Annual sales of select drugs in PsA: 2021-2031
- Drug-class-specific trends
- U.S. patient share for TNF inhibitors in PsA: 2021-2031
- EU5 patient share for TNF inhibitors in PsA: 2021-2031
- Japanese patient share for TNF inhibitors in PsA: 2021-2031
- Major-market brand and biosimilar sales of ustekinumab in PsA: 2021-2031
- Patient share of ustekinumab for PsA in the United States, EU5, and Japan: 2021-2031
- Major-market sales of IL-17 inhibitors for PsA: 2021-2031
- Major-market patient share of IL-17 inhibitors in PsA: 2021-2031
- Major-market sales and patient share of IL-23 inhibitors in PsA: 2021-2031
- Sales of apremilast for PsA in the United States, EU5, and Japan: 2021-2031
- Major-market patient share and sales of JAK inhibitors in PsA: 2021-2031
- Major-market patient share of PDE4, JAK, and TYK2 inhibitors in PsA: 2021-2031
- Sales of abatacept for PsA in the United States and EU5: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Etiology
- Risk factors for PsA
- Pathophysiology
- Clinical, extra-articular, and radiographic features of various spondyloarthropathies
- Pathogenesis
- Pathological changes in early and late PsA
- Key pathways and drug targets
- Pathogenesis and drug targets
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Total prevalent cases of psoriatic arthritis: 2022-2032 (thousands)
- Sources used for diagnosed prevalence of psoriatic arthritis
- Diagnosed prevalent cases of psoriatic arthritis: 2021-2031 (thousands)
- Sources used for diagnosed drug-treated prevalence of psoriatic arthritis
- Diagnosed drug-treated prevalent cases of psoriatic arthritis: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for PsA
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for PsA
- Current treatments used for PsA
- Market events impacting the use of key current therapies in PsA
- Advantages and disadvantages of TNF-u03b1 inhibitors
- Expert insight: TNF inhibitors
- Advantages and disadvantages of ustekinumab
- Ongoing clinical development
- Expert insight: ustekinumab
- Advantages and disadvantages of secukinumab
- Ongoing clinical development
- Expert insight: secukinumab
- Advantages and disadvantages of brodalumab
- Advantages and disadvantages of ixekizumab
- Advantages and disadvantages of guselkumab
- Ongoing clinical development
- Expert insight: guselkumab
- Risankizumab
- Advantages and disadvantages of risankizumab
- Expert insight: risankizumab
- Advantages and disadvantages of tofacitinib
- Expert insight: tofacitinib
- Upadacitinib
- Advantages and disadvantages of upadacitinib
- Expert insight: upadacitinib
- Advantages and disadvantages of apremilast
- Ongoing clinical development
- Expert insight: apremilast
- Advantages and disadvantages of abatacept
- Expert insight: abatacept
- Advantages and disadvantages of cDMARDs
- Expert insight: cDMARDs
- Medical practice
- Overview
- Factors influencing drug selection in PsA
- Treatment decision tree for PsA: United States
- Treatment decision tree for PsA: Europe
- Treatment decision tree for PsA: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in PsA
- Top unmet needs in PsA: current and future attainment
- Expert insight: unmet need in PsA
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key emerging therapies in development for PsA
- Estimated launch dates of key emerging therapies for the treatment of PsA
- Bimekizumab profile
- Key ongoing clinical trials of bimekizumab in the treatment of PsA
- Analysis of the clinical development program for bimekizumab
- Expert insight: bimekizumab
- Expectations for launch and sales opportunity of bimekizumab in psoriatic arthritis
- Tildrakizumab profile
- Key ongoing clinical trials of tildrakizumab in the treatment of PsA
- Analysis of the clinical development program for tildrakizumab
- Expert insight: tildrakizumab
- Expectations for launch and sales opportunity of tildrakizumab in PsA
- Deucravacitinib profile
- Key ongoing clinical trials of deucravacitinib in the treatment of psoriatic arthritis
- Analysis of the clinical development program for deucravacitinib
- Expert insight: deucravacitinib
- Expectations for launch and sales opportunity of deucravacitinib in psoriatic arthritis
- Early-phase pipeline analysis
- Select compounds in early-phase development for PsA
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- General reimbursement environment: United States
- General reimbursement environment: EU5
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Bibliography
- Key findings
Vaishnavi Dhiman, M.Sc., Associate Healthcare Research & Data Analyst, Immune and Inflammation. Before joining Clarivate, Ms. Dhiman was a research analyst at Prescient Healthcare Group and a drug safety associate (Regulatory) at Parexel International. She has substantial experience in secondary research, clinical trials and regulatory analysis of drug products, and competitive intelligence. She holds an M.Sc. and a B.Sc. (Honors) in microbiology from Panjab University in Chandigarh, India.